<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412019000200100</article-id>
<article-id pub-id-type="doi">10.24245/gom.v87i2.2511</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Consecuencias oncológicas y perinatales del tratamiento conservador de la fertilidad en pacientes con cáncer endometrial tratadas con progestinas]]></article-title>
<article-title xml:lang="en"><![CDATA[Oncological and perinatal results of conservative treatment of fertility in patients with endometrial cancer treated with progestins]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arteaga-Gómez]]></surname>
<given-names><![CDATA[Ana Cristina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reyes-Muñoz]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barros-Delgadillo]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado-Amador]]></surname>
<given-names><![CDATA[Denise Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Cruz]]></surname>
<given-names><![CDATA[Rosa Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cerecedo-Ponce]]></surname>
<given-names><![CDATA[Carmen Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Perinatología Isidro Espinosa de los Reyes servicio de Oncología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Perinatología Isidro Espinosa de los Reyes servicio de Endocrinología Reproductiva ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Perinatología Isidro Espinosa de los Reyes servicio de Biología de la Reproducción ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Perinatología Isidro Espinosa de los Reyes  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<volume>87</volume>
<numero>2</numero>
<fpage>100</fpage>
<lpage>109</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412019000200100&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412019000200100&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412019000200100&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO: Estimar la tasa de respuesta completa y de embarazo en mujeres con cáncer endometrial en tratamiento conservador con progestinas.  MATERIALES Y MÉTODOS: Estudio de cohorte, retrolectivo y transversal efectuado en el Instituto Nacional de Perinatología en mujeres con cáncer endometrial, en estadios tempranos, atendidas entre 2007 y diciembre de 2016. Criterios de inclusión: pacientes con límites de edad de 18 y 40 años, nulíparas, con deseo de fertilidad, haber sido tratadas con megestrol, DIU-levonorgestrel o progesterona micronizada durante seis meses. A todas las pacientes se les tomó una biopsia endometrial a los 6 y 12 meses. Se utilizó estadística descriptiva y comparaciones entre mediciones, &#967;2 o t de Student según la distribución de cada variable.  RESULTADOS: Se incluyeron 11 pacientes con cáncer endometrial con edad promedio de 32 ± 2.4 años. La biopsia tomada a los seis meses fue: respuesta completa en 6/11, respuesta parcial en 2/11 y persistencia en 2/11; en una paciente no se tomó la biopsia a los seis meses por embarazo, no hubo casos de progresión. A los 12 meses de seguimiento hubo 5 respuestas completas, 2 parciales, 2 persistencias, 1 caso de progresión de la enfermedad y otro que suspendió el tratamiento. Se efectuaron 8 ciclos de FIV en 6 pacientes con tasa de embarazo de 25%. La duración del tratamiento fue de 19.3 ± 8 meses, el seguimiento total fue de 31.6 ± 13 meses.  CONCLUSIONES: El tratamiento conservador de la fertilidad con progestinas en pacientes con cáncer endometrial, en etapas tempranas, es factible y seguro. El embarazo debe intentarse inmediatamente después de una respuesta completa.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE: To estimate the complete response rate and pregnancy in women with endometrial cancer who have received conservative treatment with progestins.  MATERIALS AND METHODS:  Cohort, retrolective and transversal study carried out in the National Institute of Perinatology, in women with endometrial cancer in early stages between 2007 and December 2016. Including patients between 18-40 years, nulliparous, with desire for fertility. The progestins used were megestrol, IUD-levonorgestrel and micronized progesterone for six months. Endometrial biopsy was performed at 6 and 12 months; The result was classified as a complete, partial response, persistence or progression of the disease. Descriptive statistics and comparisons between baseline measurements at six and 12 months are used using student grid and / or t tests according to the distribution of each variable. It is a statistical program SPSS version 23 for Windows (Chicago, USA).  RESULTS:  11 women with endometrial cancer were included. The average age of the women was 32 ± 2.4 years. Morbidity associated with hypothyroidism and type 2 diabetes mellitus. Six-month biopsy was: complete response 6/11 partial response 2/11 and persistence 2/11, in one patient the biopsy was not performed at 6 months by pregnancy, there were no cases of progression. At 12 months of follow-up, there were 5 complete responses, 2 partial responses, 2 persistences, 1 case of disease progression and one case that discontinued treatment. Eight cycles of IVF were performed in 6 patients with a pregnancy rate of 25%, the duration of treatment was 19.3 ± 8 months, the total follow-up was 31.6 ± 13 months.  CONCLUSIONS:  Conservative fertility therapy with progestins in women younger than 40 years old with early-stage endometrial cancer is feasible and secure in our institution. Pregnancy must be sought immediately after a full response to the cancer treatment. Our findings are similar to the ones found in our systematic review of the international bibliography.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Embarazo]]></kwd>
<kwd lng="es"><![CDATA[cáncer endometrial]]></kwd>
<kwd lng="es"><![CDATA[tratamiento conservador]]></kwd>
<kwd lng="es"><![CDATA[progestinas]]></kwd>
<kwd lng="es"><![CDATA[megestrol]]></kwd>
<kwd lng="es"><![CDATA[DIU levonorgestrel]]></kwd>
<kwd lng="es"><![CDATA[progesterona micronizada]]></kwd>
<kwd lng="en"><![CDATA[Pregnancy]]></kwd>
<kwd lng="en"><![CDATA[Endometrial cancer]]></kwd>
<kwd lng="en"><![CDATA[Conservative treatment]]></kwd>
<kwd lng="en"><![CDATA[Progestins]]></kwd>
<kwd lng="en"><![CDATA[Megestrol]]></kwd>
<kwd lng="en"><![CDATA[IUD-levonorgestrel or micronized progesterone, pregnancy rate]]></kwd>
<kwd lng="en"><![CDATA[Endometrial biopsy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fastrez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fertility-sparing management of gynecological cancers]]></article-title>
<source><![CDATA[Maturitas]]></source>
<year>2015</year>
<volume>82</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>141-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>NIH Instituto Nacional del Cáncer</collab>
<source><![CDATA[Tratamiento del cáncer de endometrio (PDQ) - Versión para profesionales de la salud]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruvalcaba--Limón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primer Consenso Mexicano de Cáncer de Endometrio Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"]]></article-title>
<source><![CDATA[Rev Invest Clin]]></source>
<year>2010</year>
<volume>62</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>585--605</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial Cancer]]></article-title>
<source><![CDATA[The Oncologist]]></source>
<year>2015</year>
<volume>20</volume>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalogera]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preserving fertility in young patients with endometrial cancer: current perspectives]]></article-title>
<source><![CDATA[International Journal of Women&#8217;s Health]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>691-701</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arteaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castellanos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento conservador del cáncer de endometrio como una opción para preservar la fertilidad Experiencia de cinco años en el Instituto Nacional de Perinatología Isidro Espinosa de los Reyes]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2012</year>
<volume>80</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>394-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiegratz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic and clinical effects of progestogens]]></article-title>
<source><![CDATA[The European Journal of Contraception and Reproductive Health Care]]></source>
<year>2006</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>153-61</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma]]></article-title>
<source><![CDATA[Int J Gynecol Cancer]]></source>
<year>2006</year>
<volume>16</volume>
<numero>^sSuppl. 1</numero>
<issue>^sSuppl. 1</issue>
<supplement>Suppl. 1</supplement>
<page-range>452-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>Ethics Committee of the American Society for Reproductive Medicine</collab>
<article-title xml:lang=""><![CDATA[Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee pinion]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2013</year>
<volume>100</volume>
<page-range>1224-31</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lambertini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer and fertility reservation: international recommendations from an expert meeting]]></article-title>
<source><![CDATA[BMC Medicine]]></source>
<year>2016</year>
<volume>14</volume>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dursun]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncofertility for gynecologic and non-gynecologic cancers: Fertility sparing in young women of reproductive age]]></article-title>
<source><![CDATA[Clinical Reviews in Oncology/Hematology]]></source>
<year>2014</year>
<volume>92</volume>
<page-range>258-67</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin]]></article-title>
<source><![CDATA[Gynecologic Oncology]]></source>
<year>2014</year>
<volume>133</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>229-33</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laurelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Falcone]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Scala]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Losito]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Granata]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cascella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Greggi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term oncologic and reproductive outcomes in young women with early endometrial cancer conservatively treated: An update from an institutional prospective study]]></article-title>
<source><![CDATA[Int J Gynecol Cancer]]></source>
<year>2016</year>
<volume>26</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1650-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falcone]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer]]></article-title>
<source><![CDATA[J Gynecol Oncol]]></source>
<year>2017</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Febbraro]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals]]></article-title>
<source><![CDATA[Gynecologic Oncology]]></source>
<year>2015</year>
<volume>138</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>109-14</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendonça]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fertility-preservation in endometrial cancer: is it safe? Review of the literature]]></article-title>
<source><![CDATA[JBRA Assist Reprod]]></source>
<year>2016</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>232-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Orr]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Leitao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endometrial cancer: A review and current management strategies: Part II]]></article-title>
<source><![CDATA[Gynecologic Oncology]]></source>
<year>2014</year>
<volume>134</volume>
<page-range>393-402</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endometrial cancer: A review and current management strategies: Part I]]></article-title>
<source><![CDATA[Gynecologic Oncology]]></source>
<year>2014</year>
<volume>134</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>385-92</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hormonal therapy for women with stage IA endometrial cancer of all grades]]></article-title>
<source><![CDATA[Obstetrics &amp; Gynecology]]></source>
<year>2013</year>
<volume>122</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
